- Home
- PTLO vs VNDA Comparison
PTLO vs VNDA Comparison
Compare PTLO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTLO | VNDA |
|---|---|---|
| Founded | 1963 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.4M | 474.0M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PTLO | VNDA |
|---|---|---|
| Price | $5.56 | $7.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | $8.06 | ★ $14.90 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $732,066,000.00 | $216,105,000.00 |
| Revenue This Year | $9.02 | $21.35 |
| Revenue Next Year | $5.81 | $37.40 |
| P/E Ratio | $20.59 | ★ N/A |
| Revenue Growth | 3.03 | ★ 8.72 |
| 52 Week Low | $4.41 | $3.81 |
| 52 Week High | $13.55 | $9.91 |
Technical Indicators
Market Signals| Indicator | PTLO | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 48.92 |
| Support Level | $5.34 | $7.12 |
| Resistance Level | $6.09 | $7.79 |
| Average True Range (ATR) | 0.22 | 0.31 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 52.83 | 66.39 |
Price Performance
Historical ComparisonAbout PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.